Skip to main content

Jushi Holdings Inc. Reports Second Quarter 2023 Financial Results

Gross Profit of $30.6 Million, Representing an Improvement of $3.9 Million YoY, Gross Profit Margin of 46.0%

Net Loss of $14.0 Million, Compared to Net Income of $12.1 Million in Q2 2022 and Net Loss of $12.4 Million in Q1 2023

Adjusted EBITDA of $12.6 Million, Representing Growth of $12.1 Million YoY and $5.0 Million QoQ, Adjusted EBITDA Margin of 19%

Continued Progress on Cost Savings and Efficiency Optimization Initiatives

Jushi-Branded Product Sales Continued to Approach Nearly Half of Total Retail Revenue YTD across the Company's Five Vertical Markets

BOCA RATON, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, is pleased to announce its financial results for the second quarter ended June 30, 2023 (“Q2 2023”). All financial information is unaudited and provided in U.S. dollars unless otherwise indicated and is prepared under U.S. Generally Accepted Accounting Principles (“GAAP”).

Second Quarter 2023 Financial Highlights1

  • Total revenue of $66.4 million
  • Gross profit margin was 46.0%, compared to 36.7% in the second quarter ended June 30, 2022 (“Q2 2022”) and 42.9% in the first quarter ended March 31, 2023 (“Q1 2023”)
  • Net Loss of $14.0 million, compared to net income of $12.1 million in Q2 2022 and net loss of $12.4 million in Q1 2023
  • Adjusted EBITDA1 of $12.6 million, an improvement of $12.1 million year-over-year and $5.0 million sequentially
  • Cash, cash equivalents, and restricted cash of $32.1 million as of quarter end

1 See “Use of Non-GAAP Financial Information” and “Unaudited Reconciliation of Net Income (Loss) to Adjusted EBITDA and Adjusted EBITDA Margin” below.

Second Quarter 2023 Operational Highlights

  • Strengthened balance sheet through a $20.0 million non-dilutive debt financing with FVCbank
  • Attained approximately 46.5% in Q2 2023 and approximately 47.9% YTD sell-through of Jushi-branded products across the Company’s five vertical markets
  • Achieved reduction of over 50% in retail labor hours relative to last year's peak following the implementation of an optimized retail labor model in Q2 2023
  • Filed for the employee retention credit with the Internal Revenue Service in the amount of $10.1 million

Post Quarter-End Developments

  • Increased operating performance at Pennsylvania, Virginia, and Massachusetts grower-processors with additional expected operating efficiencies to be achieved in the second half of the year
  • Expecting to launch Hijinks, our new premium flower brand with improved genetics, in multiple states as part of approximately 15 new SKUs being launched in the second half of the year
  • Starting in July 2023, began making quarterly principal payments of approximately $2.4 million on the Company’s first lien financing with Sunstream Bancorp Inc. as well as pursuing several opportunities to continue debt reduction
  • Continuing expansion of our retail footprint in Virginia, with expected opening of Woodbridge, VA by the end of August 2023, the sixth Beyond HelloTM medical cannabis dispensary in the state
  • Supporting the positive momentum surrounding the Pennsylvania bipartisan adult-use bill under active consideration

Management Commentary
“I am pleased to report the continued improvement in our profitability as we aggressively execute our cost savings and optimization initiatives across our national footprint, driving a meaningful reduction in operating expenses year-over-year,” said Jim Cacioppo, Chief Executive Officer, Chairman, and Founder of Jushi. “The significant enhancements we have made in our grower-processor facilities in Pennsylvania and Virginia have enabled us to operate more efficiently on a larger scale with increased capacity, resulting in expanded margins and wholesale revenue growth. Additionally, we have seen meaningful product quality improvements across our portfolio of brands. Jushi-branded product sell-through has remained steady across our vertical markets, representing nearly half of total retail sales. Sales are expected to increase with the Woodbridge, Virginia store opening and two Pennsylvania stores reopening as well as the launch of new, competitive, higher margin products, such as the anticipated introduction of our Hijinks brand in multiple states in the second half of the year.”

Mr. Cacioppo continued, “Notably in the second quarter, gross profit increased approximately $613 thousand sequentially, and Adjusted EBITDA grew by $12.1 million year-over-year and sequentially by approximately 66%, achieving an Adjusted EBITDA margin of approximately 19%. Our results for the quarter reflect the strides we have made toward long-term, reliable profitability as we work to deliver sustained improvements in our fundamentals. With rigorous cost controls and robust operational discipline, we believe we are positioned to achieve our goal of generating positive operating cash flow within the next few quarters.”

Financial Results for the Second Quarter Ended June 30, 2023
($ in millions) 

 Quarter Ended
June 30, 2023
Quarter Ended
June 30, 2022
Quarter Ended
June 30, 2023
Quarter Ended
March 31, 2023
Revenue$66.4 $72.8 (8.7)%$66.4 $69.9 (4.9)%
Gross profit$30.6 $26.7 14.6%$30.6 $29.9 2.0%
Operating expenses$27.2 $38.7 (29.9)%$27.2 $32.5 (16.4)%
Income (loss) from operations$3.4 $(12.1)128.2%$3.4 $(2.5)235.4%
Net income (loss)$(14.0)$12.1 (216.3)%$(14.0)$(12.4)(12.8)%
Adjusted EBITDA$12.6 $0.5 2317.6%$12.6 $7.6 66.0%

Revenue in Q2 2023 was $66.4 million as compared to $72.8 million in the second quarter of 2022. The year-over-year decrease in revenue can be attributed to a modest decline in retail sales due to the closure of three underperforming stores, in addition to headwinds in: (i) Illinois, due to the impact of the state of Missouri moving to recreational use, and (ii) Nevada and Pennsylvania, due to increased competition. The decrease in retail revenue was partially offset by new dispensary openings in Virginia and Ohio. The Company ended the quarter with thirty-four operating dispensaries in seven states, as compared to thirty-three in six states at the end of June 30, 2022. Additionally, Jushi-branded product sales grew to approximately 46.5% of total retail sales in the Company's five vertical markets in Q2 2023.

Wholesale revenue increased $1.3 million year-over-year, primarily due to continued operational improvements and increased efficiencies at our grower-processors in Massachusetts and Virginia.

Gross profit in Q2 2023 was $30.6 million compared to $26.7 million in Q2 2022, an increase of $3.9 million or 14.6% year-over-year. Gross profit margin increased to 46.0% compared to 36.7% in Q2 2022 and 42.9% in Q1 2023. The improvements in gross profit and gross profit margin were driven by operating efficiencies at the grower-processor facilities in Massachusetts and Virginia, which were partially offset by market price compression and competition in Illinois, Nevada, and Pennsylvania.

Operating expenses for Q2 2023 were $27.2 million, compared to $38.7 million in Q2 2022, a decrease of $11.6 million or 29.9% year-over-year, demonstrating the continued effectiveness of the Company’s cost savings, increased efficiency, and optimization plan. Increased savings were comprised of a decrease in the number of employees as the organization is right-sized, a reduction in retail labor hours following the implementation of a budgeted retail labor hour model, and a decrease in share-based compensation reflecting lower value of share-based compensation grants as well as forfeitures of unvested equity awards. Prior year included costs related to the Company’s transition to GAAP reporting and SEC registration.

Net loss for Q2 2023 was $14.0 million, compared to net loss of $12.4 million in Q1 2023, and to net income of $12.1 million in Q2 2022.

Adjusted EBITDA1 in Q2 2023 was $12.6 million compared to $0.5 million in Q2 2022 and $7.6 million in Q1 2023, representing an improvement of $12.1 million year-over-year and $5.0 million quarter-over-quarter.

1 See “Use of Non-GAAP Financial Information” and “Unaudited Reconciliation of Net Income (Loss) to Adjusted EBITDA and Adjusted EBITDA Margin” below.

Balance Sheet and Liquidity
As of June 30, 2023, the Company had approximately $32.1 million of cash, cash equivalents and restricted cash. In 2023, the Company expects total commitments for capital expenditures to be approximately $10.0 - $12.0 million, of which the majority is for maintenance capex as a substantial amount of expansion projects in Pennsylvania and Virginia were completed last year. As of June 30, 2023, the Company had approximately $229.4 million in principal amount of total debt, excluding leases and property, plant, and equipment financing obligations. As of August 7, 2023, the Company’s issued and outstanding shares were 196,631,598 and its fully diluted shares outstanding were 312,432,357.

Use of Non-GAAP Financial Information
We believe that the presentation of non-GAAP financial information provides important supplemental information to management and investors regarding financial and business trends relating to our financial condition and results of operations. For further information regarding these non-GAAP measures, including the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, please refer to the “Unaudited Reconciliation of Net Income (Loss) to Adjusted EBITDA and Adjusted EBITDA Margin” section of this press release.

Conference Call and Webcast Information

The Company will host a conference call to discuss its financial results for the second quarter ended June 30, 2023 at 8:00 a.m. ET today, Friday, August 11, 2023.

Event:Second Quarter 2023 Financial Results Conference Call
Date:Friday, August 11, 2023
Time:8:00 a.m. Eastern Time
Live Call:1-877-407-0792 (U.S. & Canada Toll-Free)
Conference ID:13739697

For interested individuals unable to join the conference call, a webcast of the call will be available for one year following the conference call and can be accessed via webcast on Jushi’s Investor Relations website.

About Jushi Holdings Inc.
We are a vertically integrated cannabis company led by an industry-leading management team. Jushi is focused on building a multi-state portfolio of branded cannabis assets through opportunistic acquisitions, distressed workouts, and competitive applications. Jushi strives to maximize shareholder value while delivering high-quality products across all levels of the cannabis ecosystem. For more information, visit or our social media channels, InstagramFacebookTwitter, and LinkedIn.

Forward-Looking Information and Statements   
This press release may contain “forward-looking statements” and “forward‐looking information” within the meaning of applicable securities laws, including Canadian securities legislation and United States (“U.S.”) securities legislation (collectively, “forward-looking information”) which are based upon the Company’s current internal expectations, estimates, projections, assumptions and beliefs. All information, other than statements of historical facts, included in this report that address activities, events or developments that Jushi expects or anticipates will or may occur in the future constitutes forward‐looking information. Forward‐looking information is often identified by the words, “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes, among others, information regarding: future business strategy, competitive strengths, goals, expansion and growth of Jushi’s business, operations and plans, including new revenue streams, the integration and benefits of recently acquired businesses or assets, roll out of new operations, the implementation by Jushi of certain product lines, implementation of certain research and development, the application for additional licenses and the grant of licenses that will be or have been applied for, the expansion or construction of certain facilities, the reduction in the number of our employees, the expansion into additional U.S. and international markets, any potential future legalization of adult use and/or medical marijuana under U.S. federal law; expectations of market size and growth in the U.S. and the states in which Jushi operates; expectations for other economic, business, regulatory and/or competitive factors related to Jushi or the cannabis industry generally; and other events or conditions that may occur in the future.

Readers are cautioned that forward‐looking information is not based on historical facts but instead is based on reasonable assumptions and estimates of the management of Jushi at the time they were provided or made and such information involves known and unknown risks, uncertainties, including our ability to continue as a going concern, and other factors that may cause the actual results, level of activity, performance or achievements of Jushi, as applicable, to be materially different from any future results, performance or achievements expressed or implied by such forward‐looking information. Such factors include, among others: risks relating to U.S. regulatory landscape and enforcement related to cannabis, including political risks; risks relating to anti‐money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the cannabis industry; risks related to the economy generally; risks related to inflation, the rising cost of capital, and stock market instability; risks relating to pandemics and forces of nature; risks related to contracts with third party service providers; risks related to the enforceability of contracts; the limited operating history of Jushi; Jushi’s history of operating losses and negative operating cash flows; reliance on the expertise and judgment of senior management of Jushi; risks inherent in an agricultural business; risks related to co‐investment with parties with different interests to Jushi; risks related to proprietary intellectual property and potential infringement by third parties; risks relating to the Company’s recent debt financing and other financing activities including increased leverage and issuing additional equity securities; risks relating to the management of growth; costs associated with Jushi being a publicly-traded company and a U.S. and Canadian filer; increasing competition in the industry; risks associated with cannabis products manufactured for human consumption including potential product recalls; reliance on key inputs, suppliers and skilled labor; reliance on manufacturers and contractors; risks of supply shortages or supply chain disruptions; cybersecurity risks; constraints on marketing products; fraudulent activity by employees, contractors and consultants; tax and insurance related risks; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcing judgments and effecting service outside of Canada; risks related to completed, pending or future acquisitions or dispositions, including potential future impairment of goodwill or intangibles acquired and/or post-closing disputes; sales of a significant amount of shares by existing shareholders; the limited market for securities of the Company; risks related to the continued performance of existing operations in California, Illinois, Massachusetts, Nevada, Ohio, Pennsylvania, and Virginia; risks related to the anticipated openings of additional dispensaries or relocation of existing dispensaries; risks relating to the expansion and optimization of the grower-processor in Pennsylvania, the vertically integrated facilities in Virginia and Massachusetts and the facility in Nevada; risks related to opening new facilities, which is subject to licensing approval; limited research and data relating to cannabis; risks related to challenges from governmental authorities of positions the Company has taken with respect to tax credits; and risks related to the Company’s critical accounting policies and estimates; and these and other risks identified under the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business” sections of our most recent Annual Report on Form 10-K and otherwise identified from time to time in our reports and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulators.

Although Jushi has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward‐looking information will prove to be accurate as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on the forward‐looking information contained in this press release or other forward-looking statements made by Jushi. Forward‐looking information is provided and made as of the date of this press release and Jushi does not undertake any obligation to revise or update any forward‐looking information or statements other than as required by applicable law.

Unless the context requires otherwise, references in this press release to “Jushi,” “Company,” “we,” “us” and “our” refer to Jushi Holdings Inc. and our subsidiaries.

For further information, please contact:

Investor Relations and Media Contact:
Lisa Forman
Director of Investor Relations

(In thousands of U.S. dollars, except share and per share amounts)
 Three Months Ended June 30, Six Months Ended June 30,
  2023   2022   2023   2022 
 (unaudited) (unaudited)
REVENUE, NET$66,425  $72,757  $136,298  $134,645 
COST OF GOODS SOLD (35,871)  (46,089)  (75,803)  (88,865)
GROSS PROFIT 30,554   26,668   60,495   45,780 
OPERATING EXPENSES 27,154   38,745   59,606   76,458 
INCOME (LOSS) FROM OPERATIONS 3,400   (12,077)  889   (30,678)
Interest expense, net (9,790)  (10,947)  (18,310)  (21,063)
Fair value gains on derivatives 1,090   42,572   9,120   56,881 
Other, net (190)  228   519   (70)
Total other income (expense), net (8,890)  31,853   (8,671)  35,748 
INCOME (LOSS) BEFORE INCOME TAX (5,490)  19,776   (7,782)  5,070 
Income tax expense (8,546)  (7,710)  (18,694)  (12,761)
NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) (14,036)  12,066   (26,476)  (7,691)
Less: net loss attributable to non-controlling interests           
Weighted average shares outstanding - basic 194,756,391   190,870,572   194,405,562   187,147,856 
Weighted average shares outstanding - diluted 194,756,391   205,697,153   194,405,562   208,038,283 

(In thousands of U.S. dollars, except share amounts)
 June 30, 2023
 December 31,
Cash and cash equivalents$26,784  $26,196 
Restricted cash - current 3,128    
Accounts receivable, net 5,323   4,809 
Inventory, net 40,780   35,089 
Prepaid expenses and other current assets 14,274   3,957 
Total current assets 90,289   70,051 
Property, plant and equipment, net 169,825   177,755 
Right-of-use assets - finance leases 65,245   114,021 
Other intangible assets, net 98,471   100,082 
Goodwill 38,239   38,239 
Other assets 37,271   28,243 
Restricted cash - non-current 2,150   950 
Total non-current assets 411,201   459,290 
Total assets$501,490  $529,341 
Accounts payable$21,608  $21,313 
Accrued expenses and other current liabilities 49,857   46,329 
Income tax payable 32,575   19,921 
Debt, net - current portion (including related party principal amounts of $3,254 and $3,189 as of June 30, 2023 and December 31, 2022, respectively) 14,791   8,704 
Finance lease obligations - current 8,786   11,361 
Total current liabilities 127,617   107,628 
Debt, net - non-current (including related party principal amounts of $18,526 and $17,491 as of June 30, 2023 and December 31, 2022, respectively) 198,641   180,558 
Finance lease obligations - non-current 52,699   102,375 
Derivative liabilities 3,107   14,134 
Income tax liabilities - non-current 60,492   57,200 
Other liabilities - non-current 31,454   21,555 
Total non-current liabilities 346,393   375,822 
Total liabilities 474,010   483,450 
Common stock, no par value: authorized shares - unlimited; issued and outstanding shares - 196,633,371 and 196,686,372 Subordinate Voting Shares as of June 30, 2023 and December 31, 2022, respectively.     
Paid-in capital 500,085   492,020 
Accumulated deficit (471,218)  (444,742)
Total Jushi shareholders' equity 28,867   47,278 
Non-controlling interests (1,387)  (1,387)
Total equity 27,480   45,891 
Total liabilities and equity$501,490  $529,341 

(In thousands of U.S. dollars)
 Six Months Ended June 30,
  2023   2022 
Net cash flows used in operating activities$(10,285) $(25,711)
Net cash flows used in investing activities (5,228)  (61,741)
Net cash flows provided by financing activities 20,429   36,014 
Effect of currency translation on cash and cash equivalents    (238)


EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin

In addition to providing financial measurements based on GAAP, we provide additional financial metrics that are not prepared in accordance with GAAP. We use non-GAAP financial measures, in addition to GAAP financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate our financial performance. These non-GAAP financial measures are EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin (each as defined below). We believe that these non-GAAP financial measures reflect our ongoing business by excluding the effects of expenses that are not reflective of our operating business performance and allow for meaningful comparisons and analysis of trends in our business. These non-GAAP financial measures also facilitate comparing financial results across accounting periods and to those of peer companies. As there are no standardized methods of calculating these non-GAAP measures, our methods may differ from those used by others, and accordingly, the use of these measures may not be directly comparable to similar measures used by others, thus limiting their usefulness. Accordingly, these non-GAAP measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.

EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin are financial measures that are not defined under GAAP. We define EBITDA as net income (loss), or “earnings”, before interest, income taxes, depreciation and amortization. We define Adjusted EBITDA as EBITDA before: (i) non-cash share-based compensation expense; (ii) inventory-related adjustments; (iii) fair value changes in derivatives; (iv) other (income)/expense items; (v) transaction costs; (vi) asset impairment; (vii) loss on debt extinguishment; and (viii) start-up costs. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by total revenue. These financial measures are metrics that have been adjusted from the GAAP net income (loss) measure in an effort to provide readers with a normalized metric in making comparisons more meaningful across the cannabis industry, as well as to remove non-recurring, irregular and one-time items that may otherwise distort the GAAP net income measure. Other companies in our industry may calculate this measure differently, limiting their usefulness as comparative measures.

Unaudited Reconciliation of Net Income (Loss) to Adjusted EBITDA
(In thousands of U.S. Dollars)

 Three Months Ended
June 30, 2023
 Three Months Ended
March 31, 2023
 Three Months Ended
June 30, 2022
NET INCOME (LOSS) (1)$(14,036) $(12,440) $12,066 
Income tax expense 8,546   10,148   7,710 
Interest expense, net 9,790   8,520   10,947 
Depreciation and amortization (2) 6,629   7,335   4,355 
EBITDA (Non-GAAP) 10,929   13,563   35,078 
Non-cash share-based compensation 2,363   2,311   4,684 
Inventory-related adjustments (3)    251   436 
Fair value changes in derivatives (1,090)  (8,030)  (42,572)
Other (income) expense, net (4) 418   (511)  (980)
Start-up costs (5)       991 
Transaction costs (6)    19   2,885 
Adjusted EBITDA (Non-GAAP)$12,620  $7,603  $522 

(1) Net income (loss) includes amounts attributable to non-controlling interests.
(2) Includes amounts that are included in cost of goods sold and in operating expenses.
(3) Includes: (i) inventory step-up on business combinations; (ii) inventory recall reserves; and (iii) reserves for discontinued products. The inventory step-up on business combinations relate to the fair value write-up on inventory acquired on the business acquisition date and then sold subsequent to the acquisition date. The inventory recall reserves relate to the estimated impact of the Pennsylvania Department of Health recall and ban of vape products containing certain cannabis concentrates. The ban was lifted in June 2022.
(4) Includes: (i) remeasurement of contingent consideration related to acquisitions; (ii) losses (gains) on legal settlements; and (iii) severance costs.
(5) Expansion and start-up costs incurred in order to prepare a location for its intended use. Start-up costs are expensed as incurred and are not indicative of ongoing operations of each new location.
(6) Transaction costs include: (i) registration statement costs such as professional fees and other costs relating to our SEC registration; and (ii) acquisition and deal costs.

Calculation of Adjusted EBITDA Margin
(In thousands of U.S. Dollars, unless otherwise stated)

 Three Months Ended
June 30, 2023
 Three Months Ended
March 31, 2023
 Three Months Ended
June 30, 2022
Total revenue, net$66,425  $69,873  $72,757 
Adjusted EBITDA (Non-GAAP)$12,620  $7,603  $522 
Adjusted EBITDA Margin (Non-GAAP) 19.0%  10.9%  0.7%

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.